Basis: Four-quarter operating EBITDA / current FMP quote-based enterprise value × 100. Source: stored company filings and market data; unavailable inputs remain N/A.
The EBITDA yield is N/A as of 2026-10-06T22:51:51.438Z.
Calculation as of: 2026-10-06T22:51:51.438Z.
Quote observation: 2026-10-06T20:00:01.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: a3d1fbdfc20658083391a22a35257b501cad1354629c31eed1b40f8a69f1a870
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EBITDA YIELD
N/A
Lucid Diagnostics Inc.
Market Cap
$114.46M
EBITDA Yield
N/A
| NAME | MARKET CAP | EBITDA YIELD |
|---|---|---|
| Lucid Diagnostics Inc. (LUCD) | $114.46M | N/A |
| Genelux Corporation (GNLX)vs › | $113.89M | N/A |
| Coya Therapeutics, Inc. (COYA)vs › | $113.77M | N/A |
| Foghorn Therapeutics Inc. (FHTX)vs › | $115.67M | N/A |
| Unicycive Therapeutics, Inc. (UNCY)vs › | $112.94M | N/A |
| Caribou Biosciences, Inc. (CRBU)vs › | $112.57M | N/A |
| MaxCyte, Inc. (MXCT)vs › | $116.76M | N/A |
| Spruce Biosciences, Inc. (SPRB)vs › | $117.76M | N/A |
| Tenaya Therapeutics, Inc. (TNYA)vs › | $118.59M | N/A |
| Aardvark Therapeutics, Inc. Common Stock (AARD)vs › | $110.30M | N/A |
EBITDA Yield = TTM EBITDA / Enterprise Value
EBITDA yield is the inverse of EV/EBITDA, expressing trailing pre-interest, pre-tax operating cash generation as a percentage of enterprise value. Comparable across leverage levels; higher is cheaper. Not meaningful for banks and insurers.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
